Raise closed, search for fresh raises on Seedstage

North Reading, MA

Developing cannabis-based, FDA-approved drugs for nervous system disorders through advanced nanotechnology.

• Mission: Developing FDA-approved, cannabis-based drugs to address central and peripheral nervous system disorders, including opioid use disorder, pain management, and anxiety.  
• Innovation: Utilizing advanced nanotechnology to create sustained-release formulations of cannabinoids, improving drug delivery and providing consistent therapeutic effects for chronic conditions.  
• Market Opportunity: Offering a novel approach to managing conditions like opioid addiction, chemotherapy-induced pain, and multiple sclerosis, targeting patients whose needs are only partially addressed by traditional treatments.  
• Funding Uses: Allocating funds to support pre-clinical studies, research efforts, and the scaling of manufacturing and clinical trials to bring innovative treatments to market.  
• Collaboration: Partnering with renowned institutions such as Harvard Medical School and the NIH to advance research and development in cannabis-based pharmaceuticals.  
• Sustainability Impact: Enhancing long-term patient relief through improved drug formulations, while addressing the growing demand for alternative treatments in the health and wellness industry.  

Aphios Pharma LLC is a biotechnology company based in North Reading, Massachusetts, dedicated to developing cannabis-based, FDA-approved drugs. These drugs are designed to address central and peripheral nervous system disorders, including opioid use disorder (OUD), chemotherapy-induced peripheral neuropathic pain (CIPNP), multiple sclerosis (MS), generalized anxiety disorder (GAD), and epilepsy.

The company utilizes cutting-edge nanotechnology to improve the delivery and efficacy of cannabinoids, creating sustained-release formulations that offer more consistent therapeutic effects. This approach aims to provide long-term relief for patients suffering from chronic conditions that are only partially managed by traditional treatments.

Aphios Pharma works closely with renowned institutions such as Harvard Medical School and the National Institutes of Health (NIH) to support its research efforts. Funds raised through this offering will be allocated to pre-clinical studies, marketing, rent and operational expenses, as well as personnel and legal costs necessary for the company’s continued growth and development.

Company Info

Aphios Pharma LLC develops cannabis-based pharmaceuticals for pain management and other medical conditions using innovative drug delivery technologies.

Aphios Pharma LLC focuses on developing FDA-approved cannabis-based pharmaceuticals aimed at addressing various medical conditions such as pain, cancer pain, anxiety, opioid use disorder, and multiple sclerosis. The company has identified challenges in current cannabis delivery methods, which often result in complex dosing and short-lived effects. To address these issues, Aphios is working on nano-encapsulated cannabinoids that enhance oral bioavailability and sustain release. Their research targets specific conditions like chemotherapy-induced peripheral neuropathic pain and opioid addiction, aiming to improve treatment outcomes through innovative drug delivery technologies. The company has made significant investments in research and development, raising funds to support the scaling of manufacturing and clinical trials. Additionally, Aphios has established partnerships with various pharmaceutical companies to further their drug development efforts.